Flow Cytometry The Flow Cytometry Core provides services to HCCC members from all 6 research programs conducting both laboratory and clinical cancer research. The mission of the Flow Cytometry Facility is to serve HCCC investigators by providing state-of-the-art Flow Cytometry Services including: 1) High speed sorting 2) Multi-parameter analysis 3) High efficiency purification of cell subsets 4) Training and assisting investigators with software programs available for interpretation and analysis of data 5) Individual training of the investigators and their laboratory personnel in the use of the bench-top instruments, which are subsequently available to them on a 24/7 basis. The Flow Cytometry Facility is in a constant process of developing new technology and services as requested and/or needed by HCCC investigators. Consultation is readily available to all investigators by the Director, the Technical Director and other support personnel in the facility. In 2009, 72 HCCC members with peer-reviewed research funding used the Flow Cytometry Facility.
The ability to analyze the expression of molecules on the surface and within individual cells, and to sort those cells based on expression of those molecules, is an essential tool for many cancer investigators. The cancer research supported by this shared resource provides state-of-the-art facilities and outstanding expertise in Flow Cytometry and cell sorting.
|Sabree, Shakoora; Berg, Daniel; Sato, Mariko (2018) Treatment of a pediatric patient with MET-amplified signet ring cell adenocarcinoma of the stomach with crizotinib. Pediatr Blood Cancer 65:e26984|
|Bharti, Sanjay Kumar; Sommers, Joshua A; Awate, Sanket et al. (2018) A minimal threshold of FANCJ helicase activity is required for its response to replication stress or double-strand break repair. Nucleic Acids Res 46:6238-6256|
|Reiner, Anne S; Sisti, Julia; John, Esther M et al. (2018) Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 36:1513-1520|
|Liu, Q; Kulak, M V; Borcherding, N et al. (2018) A novel HER2 gene body enhancer contributes to HER2 expression. Oncogene 37:687-694|
|Arthur, Rhonda; Wassertheil-Smoller, Sylvia; Manson, JoAnn E et al. (2018) The Combined Association of Modifiable Risk Factors with Breast Cancer Risk in the Women's Health Initiative. Cancer Prev Res (Phila) 11:317-326|
|Press, Robert H; Shu, Hui-Kuo G; Shim, Hyunsuk et al. (2018) The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys 102:1219-1235|
|Viala, Marie; Chiba, Akiko; Thezenas, Simon et al. (2018) Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. BMC Cancer 18:770|
|Madsen, Mark T; Menda, Yusuf; O'Dorisio, Thomas M et al. (2018) Technical Note: Single time point dose estimate for exponential clearance. Med Phys 45:2318-2324|
|Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398|
|Pryma, Daniel A; Chin, Bennett B; Noto, Richard B et al. (2018) Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med :|
Showing the most recent 10 out of 1080 publications